Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
US Energy-Revival---Market Perspectives Call
This piece takes a look at one of the great surprises in the U.S economy, the recent revival of the U.S. Energy industry as Russ notes in this piece, at a time when the U.S. Economy is facing so many headwinds, this has been one of the few genuine bright spots.
http://www.earningsimpact.com/Transcript/82736/SLV/iShares-Silver-Trust-(ETF)---US-Energy-Revival---Market-Perspectives-Call-(June-2013)
NIM remained a solid 322 basis points
With the liquidity in capital at adequate levels it looks like 2013 will be a markedly improved year for NBG
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91436938
NBG -NIM remains among the highest among private sector peers even on a risk adjusted basis and core income growth was strong at 21% year-on-year
http://www.earningsimpact.com/Transcript/83078/NBG/National-Bank-of-Greece-SA---Q1-2013-Earnings-Call
are fundamentals good of FFFC?
Considers the sale of machines as well as sales of fuel as potential sources for revenues
Well.. believes that can lead to cash flow positive quicker than any other path... What do you have to say guys
http://www.earningsimpact.com/Transcript/83021/JBII/JBI%2c-Inc----Business-Update-Call/Page/3
Interesting questions asked by Bloomberg, Wall street jrnal, CNBC during conf call
Timothy's answers to the questions...
http://www.earningsimpact.com/Transcript/82822/FNMA/Fannie-Mae---Q2-2013-Earnings-Call/Page/3
Foresee some very good development in the weeks for Algaeplast
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91426742
Cereplast restructuring of global operation is expected to reduce annual operating expenses by $600,000 to $800,000 per year
http://www.earningsimpact.com/Transcript/82849/CERP/Cereplast%2c-Inc----Q2-2013-Earnings-Call/Page/3
Data will be presented on September 3rd at the European Society of Cardiology.
Omecamtiv mecarbil was also the subject of an ongoing study of oral forms in a trial called COSMIC and those data are expected afterwards more likely in early 2014
Says at Canaccord conference
http://www.earningsimpact.com/Transcript/83012/CYTK/Cytokinetics%2c-Incorporated---Canaccord-Genuityandapos%3bs-33rd-Annual-Growth-Conference
During OneMedForumNY-2013 Conference -The revenue potential in Parkinson's is in excess of $1 billion.
And the most important thing is that this could treat not only Parkinson's, but several other diseases.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91426481
Amarantus Presentation at OneMedForumNY-2013 was a good one.
Developing diagnostics and protein therapeutics for diseases associated with apoptosis, very specifically Parkinson's and Alzheimer's are lead applications.
http://www.earningsimpact.com/Transcript/83025/AMBS/Amarantus-BioSciences%2c-Inc---OneMedForumNY-2013
Total monthly active users of Qihoo 360's PC based products and services reached a record 461 million compared to 425 million a year ago. Total revenue up by 108% year-over-year. Total smartphone users that have received a mobile of flagship mobile security product reached 338 million up from 275 million.
http://www.earningsimpact.com/Transcript/83180/QIHU/Q2-2013-Earnings-Call
9,000 doctors who are prescribing Vascepa.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91390288
Amarin at Canaccord Conference says that we have a sales force throughout the United States of 275 reps in 27 different districts in four separate regions. We had started a cardiovascular outcome study a year ago and we now have that study up and running in 11 countries at over 400 sites, earlier this year we announced that we had over 4,000 patients already enrolled into that study, so that's going well.
http://www.earningsimpact.com/Transcript/82999/AMRN/Canaccord-Genuityandapos%3bs-33rd-Annual-Growth-Conference
In Western Europe which includes the UK, generated $11.6 million or 37% of total revenue
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91389787
Velti plc Earnings in Q2
advertising contributed approximately $8.9 million to total revenues, while mobile marketing revenues comprised the remaining
http://www.earningsimpact.com/Transcript/82961/VELT/Velti-plc---Q2-2013-Earnings-Call/Page/2
Saw a clear hypoglycemia advantage for the AFREZZA -Gen2 group.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91389299
Cough observed to be the common adverse event in AFREZZA treated subjects.
Mannkind discusses more during business update call
http://www.earningsimpact.com/Transcript/82905/MNKD/Business-Update-Call
Qihoo 360 Technology Co. Ltd. Q2 2013 Earnings Call at 7.30 am ET today
Geoffrey Cook on product to market & mobile growth opportunity..
A good portion of MeetMe's revenue comes from mobile advertising..
http://www.earningsimpact.com/Transcript/83018/MEET/MeetMe-Inc---Canaccord-Genuityandapos%3bs-33rd-Annual-Growth-Conference
CEO stresses on some exciting synergies they have with bavituximab
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91387747
Sino Agro Targets record revenue of between 240 million to 280 million in 2013
Oh.. This represents a yearly growth of 73% to 102%
http://www.earningsimpact.com/Transcript/83075/SIAF/Sino-Agro-Food%2c-Inc----Q1-2013-Earnings-Call/Page/2
Provides an overview of corporate responsibility program activities & strategies.
http://www.earningsimpact.com/Transcript/83202/AMD/Advanced-Micro-Devices%2c-Inc----Business-Update-Call
Peregrine Pharma at Wedbush-2013-Life-Sciences-Management-Access-Conference
Have two Phase III ready clinical programs bavituximab which is their lead program, and Cotara program. They have FDA agreements for both of those compounds for Phase III trial designs.
http://www.earningsimpact.com/Transcript/82836/PPHM/Peregrine-Pharmaceuticals---Wedbush-2013-Life-Sciences-Management-Access-Conference
pls provide SA link
when is the conference event? anybody knows?
2-4 months? long period
Must read- Amarin presentation at Canaccord Conference
Evolving therapies for improved cardiovascular care through lipid management & more gets discussed.
http://www.earningsimpact.com/Transcript/82999/AMRN/Canaccord-Genuityandapos%3bs-33rd-Annual-Growth-Conference
Business update Conference call Transcript here
http://www.earningsimpact.com/Transcript/83021/JBII/JBI%2c-Inc----Business-Update-Call
Read here TQNT Presentation at Canaccord-Annual-Growth-Conference
http://www.earningsimpact.com/Transcript/83009/TQNT/TriQuint-Semiconductor%2c-Inc----Canaccord-Genuity%c3%a2%e2%82%ac%e2%84%a2s-33rd-Annual-Growth-Conference
Q2 call transcript updates
Large panel display driver accounted for 31.1% of our total revenue during the second quarter compared to 42.1% a year ago and 34.2% in last quarter
http://www.earningsimpact.com/Transcript/82968/HIMX/Himax-Technologies%2c-Inc----Q2-2013-Earnings-Call
Q2 call updates
Media product revenue was RMB945 million which was up 22% on a year-over-year basis
http://www.earningsimpact.com/Transcript/82825/DANG/Q2-2013-Earnings-Call
Interesting questions asked by bloomberg, cnbc, national mortgage & others during conference call QA session.
http://www.earningsimpact.com/Transcript/82822/FNMA/Q2-2013-Earnings-Call/Page/4
Italian team is working on several significant contracts and hopeful that within weeks may report several new contracts
http://www.earningsimpact.com/Transcript/82849/CERP/Cereplast%2c-Inc----Q2-2013-Earnings-Call/Page/2
Welcome.. but did you buy that? what do you think is it worth it?
Go through their last presentation before today's presentation at Canaccord
http://www.earningsimpact.com/Transcript/81869/AMRN/Amarin-Corporation-PLC---Jefferies-2013-Global-Healthcare-Conference
Canaccord Genuity’s Annual Growth Conference transcript here on-demand
http://www.earningsimpact.com/OnDemand.aspx
Canaccord Annual Growth Conference transcript on demand here
http://www.earningsimpact.com/OnDemand.aspx
Wedbush 2013 Life Sciences Management Access Conference transcript available on demand
http://www.earningsimpact.com/OnDemand.aspx